Hjalmar Flygt

Hjalmar Flygt (MD, PhD) is a specialist physician in internal medicine. He has a broad interest and experience in the field of internal medicine, with a clinical focus on emergency medicine, thromboembolic and cardiovascular diseases.

Hjalmar conducts research in the field of hematology with a focus on chronic myeloid leukemia, including clinical phase II trials as well as genetic and registry-based studies. Hjalmar has been a CTC associate since 2019 and has served as a co-investigator in 20+ early phase clinical trials.

Latest publications

Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study 11 January, 2022

Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study 21 August, 2021

Successful tyrosine kinase inhibitor discontinuation outside clinical trials – data from the population-based Swedish chronic myeloid leukaemia registry 30 March, 2021

Neurosurgical untethering with or without syrinx drainage results in high patient satisfaction and favorable clinical outcome in post-traumatic myelopathy patients 29 March, 2018

We provide our customers with cost-effective advice, conduct and reporting of clinical trials.

Contact us